Latest Strategy Changes News

Alpha HPA Limited reports significant progress on its HPA First Project Stage 2 construction and secures $30 million funding, while signing new letters of intent with leading semiconductor OEMs.

ASF Group Limited reported a solid cash position of $2.44 million as of September 2025, driven by strategic investment moves and technology development, while extending its share buyback program.

Larvotto Resources has greenlit the Hillgrove Antimony-Gold Project development, securing $175 million in funding and reporting strong high-grade drilling results that bolster its resource base.

Blue Star Helium has officially commenced construction on its Galactica helium production facility, with first helium output expected by December 2025. The project remains on track for progressive ramp-up through mid-2026.

Anagenics Limited reports a notable improvement in operating cash outflows for 1Q26, driven by cost efficiencies and strong brand performance, with Bouf Haircare on track to exceed $9 million in sales.

Celsius Resources reports steady progress on its Maalinao-Caigutan-Biyog copper-gold project, supported by promising drilling outcomes and critical bridge financing. The company also advances social and environmental initiatives while preparing for operational readiness.

Galan Lithium has completed a $20 million placement and secured Argentine government incentives, advancing its Hombre Muerto West lithium project toward first production in early 2026.

Austral Gold’s Q3 report reveals a sharp production drop at Guanaco following a fatal accident, prompting a downward revision of 2025 output and cost hikes, while Casposo’s refurbishment signals a new growth phase.

DXN Limited reports a sharp revenue decline in Q1 FY26 due to client-driven project deferrals but highlights a robust $11.9 million backlog and the imminent launch of its first Data Centre as a Service site.

West Cobar Metals reports significant progress across its WA and NSW projects, with promising assay results for rare earths and base metals, alongside strategic engagement in the US market and a recent $1.25 million capital raise.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Prairie Lithium has fast-tracked its flagship Saskatchewan lithium project by initiating fabrication of a commercial-scale extraction unit and securing vital rail access, supported by a US$5 million non-dilutive capital raise and a promising offtake agreement.